CSP
RANI icon

Cary Street Partners’s Rani Therapeutics RANI Stock Holding History

Cary Street Partners’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.02K Hold
10,550
– – ﹤0.01% 1074
2026
Q1 		$7.75K Hold
10,550
– – ﹤0.01% 973
2025
Q4 		$14.2K Buy
+10,550
New +$15.9K ﹤0.01% 964

Other funds holding RANI

CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
TIA
Traphagen Investment Advisors Oradell, New Jersey $1.4B AUM 19.32% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EL
EWA LLC Pittsbugh, Pennsylvania $548M AUM 35.14% 1-Year Est. Return

Cary Street Partners's RANI Position: Q2 2026 in Review

Cary Street Partners held its Rani Therapeutics (RANI) position steady in Q2 2026 at 10,550 shares worth $8.02K. The position accounts for ﹤0.01% of the portfolio, ranked #1074.

Cary Street Partners first reported a position in RANI in Q4 2025 and has held it in 3 quarters since. The position peaked at $14.2K in Q4 2025. 5 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Cary Street Partners held 10,550 shares of Rani Therapeutics worth $8.02K as of Q2 2026.
  • Cary Street Partners left its Rani Therapeutics share count unchanged in Q2 2026.
  • Rani Therapeutics made up ﹤0.01% of Cary Street Partners's portfolio in Q2 2026, its #1074 holding.
  • Cary Street Partners first reported a position in Rani Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Cary Street Partners's Rani Therapeutics position peaked at $14.2K in Q4 2025.
  • 5 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.